# β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

> **NCT00672841** · NA · COMPLETED · sponsor: **Duke University** · enrollment: 64 (actual)

## Conditions studied

- Invasive Candidiasis

## Interventions

- **DRUG:** Preemptive Therapy with Anidulafungin
- **DRUG:** Empiric antifungal therapy based on physician discretion.

## Key facts

- **NCT ID:** NCT00672841
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00672841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00672841, "β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00672841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*